<SEC-DOCUMENT>0001640334-19-002544.txt : 20191206
<SEC-HEADER>0001640334-19-002544.hdr.sgml : 20191206
<ACCEPTANCE-DATETIME>20191206161310
ACCESSION NUMBER:		0001640334-19-002544
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20191202
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
FILED AS OF DATE:		20191206
DATE AS OF CHANGE:		20191206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARTELO BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0001621221
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-BUSINESS SERVICES, NEC [7389]
		IRS NUMBER:				331220924
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38951
		FILM NUMBER:		191273253

	BUSINESS ADDRESS:	
		STREET 1:		888 PROSPECT STREET, SUITE 210
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		760-943-1689

	MAIL ADDRESS:	
		STREET 1:		888 PROSPECT STREET, SUITE 210
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	REACTIVE MEDICAL INC.
		DATE OF NAME CHANGE:	20170207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KNIGHT KNOX DEVELOPMENT CORP.
		DATE OF NAME CHANGE:	20141001
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>artl_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html><head><title>artl_8k.htm</title><!--Document Created by EDGARMaster--></head><BODY spellcheck="true" style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px">&nbsp; <table style="FONT-SIZE: 1px" cellspacing="0" cellpadding="0" width="100%" border="0"><tr><td><div style="HEIGHT: 4px; WIDTH: 100%; BACKGROUND: #000000; MARGIN: 0px 0px 2px" name="hrule"></div><div style="HEIGHT: 2px; WIDTH: 100%; BACKGROUND: #000000" name="hrule"></div></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px" align="center"><b>UNITED STATES</b></p><p style="MARGIN: 0px" align="center"><b>SECURITIES AND EXCHANGE COMMISSION </b></p><p style="MARGIN: 0px" align="center"><b>Washington, D.C. 20549</b></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px" align="center"><b><font size="5">FORM 8-K</font></b></p><p style="MARGIN: 0px" align="center">&nbsp;</p><p style="MARGIN: 0px" align="center"><b>CURRENT REPORT</b></p><p style="MARGIN: 0px" align="center">Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px" align="center">Date of Report (Date of earliest event reported): <b>December 2, 2019</b></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="50%" align="center" bgcolor="#ffffff" border="0"><tr height="15"><td style="BORDER-BOTTOM: 1px solid" width="46%"><p style="MARGIN: 0px" align="center"><b><font size="5">ARTELO BIOSCIENCES, INC.</font></b></p></td></tr><tr height="15"><td width="46%"><p style="MARGIN: 0px" align="center">(Exact name of registrant as specified in its charter) </p></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="85%" align="center" bgcolor="#ffffff" border="0"><tr height="15"><td style="BORDER-BOTTOM: 1px solid" width="21%"><p style="MARGIN: 0px" align="center"><b>Nevada</b></p></td><td width="4%"><p style="MARGIN: 0px" align="center">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" width="21%"><p style="MARGIN: 0px" align="center"><b>333-199213</b></p></td><td width="4%"><p style="MARGIN: 0px" align="center">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" width="21%"><p style="MARGIN: 0px" align="center"><b>33-1220924</b></p></td></tr><tr height="15"><td width="21%"><p style="MARGIN: 0px" align="center">(State or other jurisdiction of incorporation)</p></td><td width="4%"><p style="MARGIN: 0px" align="center">&nbsp;</p></td><td width="21%"><p style="MARGIN: 0px" align="center">(Commission File Number)</p></td><td width="4%"><p style="MARGIN: 0px" align="center">&nbsp;</p></td><td width="21%"><p style="MARGIN: 0px" align="center">(IRS Employer Identification No.)</p></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="85%" align="center" bgcolor="#ffffff" border="0"><tr height="15"><td style="BORDER-BOTTOM: 1px solid" width="32%"><p style="MARGIN: 0px" align="center"><b>889 Prospect Street, Suite 210, La Jolla, CA USA</b></p></td><td width="7%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" width="32%"><p style="MARGIN: 0px" align="center"><b>92037</b>&nbsp;</p></td></tr><tr height="15"><td width="32%"><p style="MARGIN: 0px" align="center">(Address of principal executive offices)</p></td><td width="7%"><p style="MARGIN: 0px">&nbsp;</p></td><td width="32%"><p style="MARGIN: 0px" align="center">(Zip Code)</p></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px" align="center">Registrant&#8217;s telephone number, including area code <b>760-943-1689</b></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px" align="center">______________________________________________________</p><p style="MARGIN: 0px" align="center">(Former name or former address, if changed since last report.)</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><font face="Wingdings"><font style="FONT-FAMILY: Wingdings">&#168;</font> </font>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><font face="Wingdings"><font style="FONT-FAMILY: Wingdings">&#168;</font> </font>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><font face="Wingdings"><font style="FONT-FAMILY: Wingdings">&#168;</font> </font>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><font face="Wingdings"><font style="FONT-FAMILY: Wingdings">&#168;</font> </font>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px">Securities registered pursuant to Section 12(b) of the Act:</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"><tr height="15"><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="38%"><p style="MARGIN: 0px"><b>Title of each class</b></p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="20%"><p style="MARGIN: 0px"><b>Trading </b><b>Symbol(s)</b></p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="40%"><p style="MARGIN: 0px"><b>Name of each exchange on which registered</b></p></td></tr><tr height="15"><td style="BORDER-BOTTOM: 1px solid" valign="top"><p style="MARGIN: 0px">Common Stock, par value $0.001 per share</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom"><p style="MARGIN: 0px">ARTL</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom"><p style="MARGIN: 0px">The Nasdaq Stock Market, LLC</p></td></tr><tr height="15"><td valign="top"><p style="MARGIN: 0px">Warrants</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">ARTLW</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">The Nasdaq Stock Market, LLC</p></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). </p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px">Emerging growth company <font face="Wingdings">x</font></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp; <font style="FONT-FAMILY: Wingdings">&#168;</font><font face="Wingdings"><font style="FONT-FAMILY: Wingdings"></font></font></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="FONT-SIZE: 1px" cellspacing="0" cellpadding="0" width="100%" border="0"><tr><td><div style="HEIGHT: 2px; WIDTH: 100%; BACKGROUND: #000000; MARGIN: 0px 0px 2px" name="hrule"></div><div style="HEIGHT: 4px; WIDTH: 100%; BACKGROUND: #000000" name="hrule"></div></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"><tr><td class="hpbhr">&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr><tr><td>&nbsp;</td></tr></table></p><p style="MARGIN: 0px"><b>Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></p><p style="MARGIN: 0px">&nbsp;&nbsp;</p><p style="MARGIN: 0px"><i>Appointment of Director</i></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">On December 6, 2019, the board of directors (the &#8220;Board&#8221;) of Artelo Biosciences, Inc. (the &#8220;Company&#8221;) appointed John W. Beck to the Board, effective immediately, with a term expiring at the Company&#8217;s 2020 annual meeting of stockholders. Mr. Beck will also serve as the Chair of the audit committee of the Board.&nbsp;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">&nbsp;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">Mr. Beck, age 59, has served as the Senior Vice President and Chief Financial Officer at Ritter Pharmaceuticals, Inc., a publicly traded pharmaceutical company, since May 2018. From 2008 until its acquisition by AstraZeneca in 2012, Mr. Beck, served first as a board member and later as Chief Financial Officer and Senior Vice President of finance &amp; operations of Ardea Biosciences Inc. (&#8220;Ardea&#8221;). Before joining Ardea, Mr. Beck spent 10 years with Metabasis Thereapeutics Inc., as a Co-Founder and its Chief Financial Officer. Since leaving Ardea in 2012, Mr. Beck has been serving as a board member and advisor to August Therapeutics, Inc., a San Diego California-based company developing non-systemic therapeutics to treat disordered eating and obesity, and Pinnacle Medical Holdings, LLC, a Denver Colorado-based physician-led network of health-care providers, which was acquired by OnPoint Medical Group, LLC in August 2017. Mr. Beck also serves as a financial mentor to UCSD&#8217;s TRITON Funds. Mr. Beck holds a Bachelor&#8217;s degree in Accounting from the University of Washington, Seattle and a Bachelor&#8217;s degree in Theology from a Seattle-area seminary.</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">&nbsp;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">Mr. Beck was granted an option to purchase 40,000 shares of the Company&#8217;s common stock vesting monthly over a four year period for his service on the Board plus a second option to purchase 10,000 shares of the Company&#8217;s common stock vesting monthly over a two year period for his service as the Chair of the Audit Committee (collectively, the &#8220;Options&#8221;) in each case subject to Mr. Beck&#8217;s continued service to the Company. The Options are subject to the terms and conditions of the Company&#8217;s 2018 Equity Incentive Plan and the related stock option agreement. Mr. Beck will also be eligible for equity award grants on the same terms as other non-employee members of the Board. On the date that is the earlier of (i) the one (1) year anniversary of Mr. Beck&#8217;s start date or (ii) the date on which the Company raises at least $7,500,000 in an equity financing, the Company intends to pay Mr. Beck an annual cash retainer payable in quarterly installments. The Company expects the compensation to be $15,000 to $20,000 per year for the first year and $20,000 to $30,000 for the second year and thereafter.</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">&nbsp;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">We will also reimburse Mr. Beck for all reasonable expenses in connection with his services to us. Mr. Beck executed the Company&#8217;s standard form of indemnification agreement, which form has been filed as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K (File No. 333- 199213) filed with the Securities and Exchange Commission on May 8, 2017, and is incorporated herein in its entirety by reference.</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">There is no arrangement or understanding between Mr. Beck and any other persons pursuant to which Mr. Beck was selected as a director. In addition, Mr. Beck is not a party to any transaction, or series of transactions, required to be disclosed pursuant to Item 404(a) of Regulation S-K.</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px" align="justify"><i>Resignation of Director</i></p><p style="MARGIN: 0px" align="justify">&nbsp;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">On December 2, 2019, Georgia Erbez resigned from the Board effective immediately. The Board will continue to qualify as &#8220;independent&#8221; under Nasdaq listing standards following her resignation. Ms. Erbez&#8217;s resignation was not the result of any disagreement with the Company on any matter relating to the Company&#8217;s operations, policies or practices.</p><p style="MARGIN: 0px"><br></p><p style="MARGIN: 0px"><table id="pagebreakbe2748a5-f171-42e6-992a-8c4969baf905" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"><tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">2</td></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr><tr><td>&nbsp;</td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px" align="center"><b>SIGNATURES</b></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"><tr height="15"><td width="29%"><p style="MARGIN: 0px"><b>ARTELO BIOSCIENCES, INC.</b></p></td><td width="55%"></td></tr><tr height="15"><td width="29%"></td><td width="55%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr height="15"><td style="BORDER-BOTTOM: 1px solid" width="29%"><p style="MARGIN: 0px"><i>/s/ Gregory D. Gorgas</i></p></td><td width="55%"><p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr><tr height="15"><td width="29%"><p style="MARGIN: 0px">Gregory D. Gorgas</p></td><td width="55%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr height="15"><td width="29%"><p style="MARGIN: 0px">President &amp; Chief Executive Officer</p></td><td width="55%"></td></tr><tr height="15"><td width="29%"></td><td width="55%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr height="15"><td width="29%"><p style="MARGIN: 0px">Date December 6, 2019</p></td><td width="55%"></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"><tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">3</td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p></BODY><!--Document Created by EDGARMaster--></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
